To determine the origin of Treg cells in cancer, we used an experimental model in which immune response, of both effector and Treg cells, to tumor-associated antigens can be characterized in mice with a restricted and readily characterized CD4+ T cell repertoire. The gene discussed is CD4; the disease is neoplasm.